Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.
Abzena has negotiated the lease on a 50,000 square foot site in San Diego as part of a $17m remodelling of its bioproduction and conjugation facilities.
Genzyme has filed a patent application for a technology platform that will bridge the gap between upstream and downstream processing in continuous biomanufacturing.
Biopharmas scaling-up production should use fluid dynamics to make better predictions about bioreactor performance according to one expert, who says engineers can use it to test multiple configurations more rapidly.
Sartorius has confirmed it will make the Ambr microreactor technology it acquired with Tap Biosystems compatible with its own downstream processing systems.
Sartorius Stedim Biotech (SSB) has launched a new small-scale bioreactor citing growing biopharmaceutical company demand for scale-up technologies as the key driver for its development.
Pall and New Brunswick have teamed up to develop and supply new disposable bioreactor technologies, targeting growing demand for products that improve quality and reduce cost of biomanufacturing.
Xcellerex is building a second cGMP FlexFactory biomanufacturing facility to support clients transitioning to their own plants and provide contract manufacturing services.
Microfluidics chose Interphex 2010 in New York, US to unveil a new processing technology that it claims can help manufacturers save time and money by switching from batch to continuous particle production.
SAFC Biosciences hopes Ex-Cell Antifoam, its new foam control product for cell culture bioreactors, will work the biomanufacturing sector into a lather.
Flexibility is going to be a key driver for the pharmaceutical market in the next few years, according to Millipore's VP of downstream processing Paul Chapman.
Boehringer Ingelheim and Slovenian company BIA Separations have
collaborated on a new separation and purification system that
should improve the production of plasmid DNA.
In an unusual move, Finnish science park Medipolis has set up a new
Good Manufacturing Practice (GMP) pilot plant to take advantage of
the growing demand for biopharmaceutical production capacity.
